New hypolipidemic drugs from the group of reductase inhibitors GMG-CoA


Cite item

Full Text

References

  1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
  2. Shepherd J., Cobbe S. M., Isles С. G. et al. Prevention of coronary heart disease with pravestatin in men with hypercholesterolemia. N. Engl. J. Med. 1995; 333: [301-1307.
  3. Sacks F. N.. Pfeffer M. A., Moye L. A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level. Ibid. 1996; 335: 1001 - 1009.
  4. La Rosa J. C., He J. H., Vupputuri S. Effect of statins on risk of coronary disease. A metaanalysis of randomized controlled trials. J. A. M. A. 1999; 282: 2340-2346.
  5. Сусеков А. В. Обоснование увеличения доз статинов в клинической практике. Тер. арх. 2001; 4: 76-80.
  6. Сусеков А. В., Кухарчук В. В. Лескол в современной клинической практике. Клин, фармакол. и тер. 2001; 4, прил.: 1-9.
  7. Black D. M., Nakker-Arkema R. С., Nawrocki J. W. An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reducrase inhibitor. Arch. Intern. Med. 1998; 158: 577-584.
  8. Marais A. D., Firth J. C., Bateman M. E. et al. Atorvastatin, an . effective lipid-modifying agent in familial hypercholesterolaemia. Arteriosclerosis Thromb. Vase. Biol. 1997; 17: 1527- 1531.
  9. Fitrberg С. D., Bertram P. Withdrawal of cerivastatin from the world market. Commentary, http://cvm.controlled-trials.com/content/2/5/205.
  10. Olsson A. G., Pears J. S., McKellar J. et al. Pharmacodynamics of a new HMG-Co-A reductase inhibitor ZD-4522 in patients with primary hypercholesterolaemia. Atherosclerosis 2000; 151(1): 39.
  11. Sasaki J., Ikeda Y., Yamamoto K. et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, NK-104 in patients with hypertriglycerideamia-randomized ciouble-blinde, cross-over placebo-controlled study. Ibid. 73.
  12. Buckett L., Ballard P., Davidson R. et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells. Ibid. 41.
  13. Smith G., Davidson R., Bloor S. et al. Pharmacological properties of ZD-4522 - a new HMG-CoA reductase inhibitor. Ibid. 39.
  14. Nezesa K., Higaki K., Hasegawa H. et al. Uptake of HMGKoA reductase inhibitor ZD-4522 into hepatocytes and distribution into liver and other tissues of the rat. Ibid. 39.
  15. Warwick M. J., Dane A. L., Raza A., Schneck D. W. Single and multiple-dose pharmacokinetics and safety of the new HMGCoA reductase inhibitor ZD-4522. Ibid. 39.
  16. Holfgate G. A., Ward W. H. J., Davidson R. G. et al. Kineticks of inhibition of HMG-CoA reducrase be a new statin, rosuvastatin. Ibid. 2001; 2(2): 47.
  17. McTaggart F., Buckett L., Davidson R. et al. Preclinical pharmacology of rosuvastatin, a new 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitor. Am. J. Cardiol. 2001; 87(suppl. I): 28-32.
  18. Olsson A. G Statin therapy and reduction in low-density lipoprotein cholesterol: initial clinical data on the potent new statin rosuvastatin. Ibid. 33-36.
  19. Olsson A. G., Pears J., McKellar J. et al. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolaemia. Ibid. 88(5): 504-508.
  20. Knopp R. H. Drug treatment of lipid disorders. N. Engl. J. Med. 1999; 341: 498-511.
  21. Wierzbicki A. S., Lumb P. J., Chick G., Crook M. A. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia. Int. J. Clin. Pract. 1999; 53(8): 609-611.
  22. Paoletti R., Fahmy M., Mahla G. et al. Rosuvastatin is more effective than pravastatin or simvastatin at improving the lipid profiles of hypercholesterolaemic patients. Atherosclerosis 2001; 2(2): 87.
  23. Stein E., Strait K. I., Miller E. et al. Rosuvastatin (20, 40 and 80 mg) reduces LDL-C, raises HDL-C and achieves treatment goals more effectivelly than atorvastatin (20, 40 and 80 mg) in patients with heterozygous familial hypercholesterolaemia. Ibid. 47.
  24. Yamamoto A., Kawagtichi A. On behalf of the Rosuvastatin Early Phase II Japanese Trials Group. Rosuvastatin provides potent, dose-dependent lipid-lowering effects in Japanese patients with primary hypercholesterolaemia. Ibid. 47.
  25. Hatsukami T. S., Zhao X.-O., Yattn С. et al. Study design for a randonized, double-blinde trial to assess the effect of 24 months of dosing with rosuvastatin on progression of carotid artery atheroma in moderately hypercholesterolemic patients with asymptomatic carotid atherosclerosis. Ibid. 47.
  26. Smilde T. J., Wissen S. V., Wollerheim H. et al. Effect of aggressive versus conventional lipid-lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-881.
  27. Stalker T. J., Lefer A. M., Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br. J. Pharmacol. 2001; 133(3): 406-412.
  28. Kajinami K., Koizumi J., Veda K. et al. Effects of NK-104, a new hydroxymethylglytaryl-coenzymeA. reductase inhibitor, on low density lipoprotein cholesterol in heterozygous familial hypercholesteroleamia. Am. J. Cardiol. 2000; 85: 178-183.
  29. Suzuki H., Yamazaki H., Aoki T. et al. Hypolipidemic effecl of NK-104 and other 3-hydroxy-3-methylglytaryl coenzyme A reductase inhibitors in guinea pigs. Arzneimittelforschung 2001; 51(1): 38-34.
  30. Fujino H., Yamada I., Shimada S. et al. Studies on the metabolic fate of itavastatin, a new inhibitor of HMG-CoA reductase in vitro metabolism. Atherosclerosis 2000; 151(1): 50.
  31. Teramoto Т., Saito Y., Nakaya N. for Japan Itavastatin Clinical Study Group. Clinical evaluation of NK-104 (itavastatin) in long-term treatment of patients with hyperlipidemia. Ibid. 53.
  32. Yamada N., Saito Y., Akanuma Y. Effect of itavastatin on lipid metabolism in N1DDM patients with hyperlipidemia. Ibid. 48.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies